Form 4: C4 Therapeutics Officer Reports Stock Transactions
SEC Form 4 Filing
Scott N. Boyle, Chief Business Officer of C4 Therapeutics, reports acquisition and disposal of common stock and stock options.
Summary
- Scott N. Boyle, Chief Business Officer of C4 Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On February 13, 2025, 1,735 shares of common stock were withheld to cover tax obligations at a price of $3.2.
- On February 14, 2025, Boyle acquired 56,500 shares of common stock in the form of RSUs, and sold 490 shares at $3.15.
- An additional 2,368 shares were withheld for taxes at $3.18 on February 14, 2025.
- On February 18, 2025, 669 shares were sold at $3.15.
- Boyle also acquired a stock option for 84,700 shares at an exercise price of $3.18, expiring on February 13, 2035.
- These transactions were made under a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing primarily reflects routine transactions related to compensation and tax obligations. The acquisition of RSUs and stock options is a positive sign, but the sales are neutral as they are part of a pre-arranged trading plan.
Positives
- Acquisition of 56,500 shares in the form of RSUs indicates a continued stake in the company's future.
- Acquisition of a stock option for 84,700 shares suggests confidence in the company's long-term performance.
Negatives
- Sales of shares totaling 1,159 shares may be perceived negatively, although they are part of a pre-arranged trading plan.
Risks
- The vesting schedule of the RSUs and stock options could influence the executive's decisions regarding their tenure with the company.
- Market fluctuations could impact the value of the shares and options, affecting the executive's overall compensation.
Future Outlook
The vesting schedule of the RSUs and stock options suggests a continued alignment of the executive's interests with the company's performance over the coming years.
Industry Context
Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's prospects.
Comparison to Industry Standards
- Comparing the vesting schedules and option grants to similar biotech companies like Arvinas or Kymera Therapeutics would provide context on the competitiveness of C4 Therapeutics' executive compensation packages.
- Analyzing the frequency and volume of insider trading activity relative to peers can offer insights into the overall sentiment surrounding the company's stock.
Stakeholder Impact
- Shareholders may monitor these filings to understand insider sentiment and potential impacts on stock price.
- Employees may be interested in the vesting schedules of RSUs and stock options as they relate to their own compensation packages.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 02/13/2025 | Shares withheld for tax obligations |
| 02/14/2025 | Acquisition of RSUs and sale of common stock |
| 02/18/2025 | Sale of common stock |
| 02/14/2026 | First vesting date of RSUs |
| 02/13/2035 | Expiration date of stock option |
Keywords
C4 Therapeutics, CCCC, Form 4, Beneficial Ownership, Stock Transactions, RSUs, Stock Options, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.